@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_head { this: np:hasAssertion dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_assertion; np:hasProvenance dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_provenance; np:hasPublicationInfo dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_publicationInfo; a np:Nanopublication . dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_assertion a np:Assertion . dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_provenance a np:Provenance . dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_publicationInfo a np:PublicationInfo . } dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_assertion { miriam-gene:5715 a ncit:C16612 . lld:C0001430 a ncit:C7057 . dgn-gda:DGN255f9a2303195be056f831c8af127627 sio:SIO_000628 miriam-gene:5715, lld:C0001430; a sio:SIO_001121 . } dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_provenance { dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_assertion dcterms:description "[Significant (P < 0.05) differences were noted between functional versus nonfunctional adenomas (percent aneuploidy, percent S phase, p27Kip1 labeling indices [LI], male sex, tumor size, and frequency of visual disturbance); Cushing's versus silent adrenocorticotropin adenomas (percent hypertetraploidy, p53 LI, tumor size, visual disturbance, and resectability); untreated versus medically treated prolactin cell adenomas (MIB-1 LI, p53 LI, and resectability); untreated versus medically treated growth hormone-containing adenomas (percent diploidy, percent S phase, MIB-1 LI, p53 LI, and p27 LI); untreated prolactin cell adenomas versus premetastatic tumors (percent hypertetraploidy, PCNA LI, p53 LI, invasiveness, and resectability); untreated growth hormone-containing adenomas versus premetastatic tumors (percent diploidy, percent S phase, PCNA LI, p53 LI, invasiveness, and resectability); Cushing's adenomas versus premetastatic tumors (percent diploidy, percent hypertetraploidy, percent S phase, MIB-1 LI, p53 LI, tumor size, invasiveness, visual disturbance, and resectability); Nelson's adenomas versus premetastatic tumors (p53 LI, tumor size, invasiveness, and resectability); silent adenomas as a whole versus nonfunctional adenomas (percent nondiploid, percent S phase, invasiveness, and respectability); silent adrenocorticotropin adenomas I and II versus silent adenoma Subtype III (invasiveness); silent adrenocorticotropin adenoma Subtypes I and II versus premetastatic tumors (MIB-1 LI and invasiveness); silent adenoma Subtype III versus premetastatic tumors (PCNA and p53 LI); and premetastatic tumors versus metastatic pituitary carcinomas (MIB-1 LI).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:16883174; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP562366.RAH1ij8WcGNbcOxChjnGIeVLiTwWUkV7jj4P3WU6MsYQ0130_publicationInfo { this: dcterms:created "2016-05-13T12:46:00+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }